nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.12.2022 | Review

Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose–response meta-analysis of cohort studies

verfasst von: T. Li, Y. Zhao, X. Yang, Y. Feng, Y. Li, Y. Wu, M. Zhang, X. Li, H. Hu, J. Zhang, L. Yuan, Y. Liu, X. Sun, P. Qin, C. Chen, D. Hu

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Insulin-like growth factor-1 (IGF-1) has increasingly been reported as linked to cardiovascular (CV) events; however, reported results have been inconsistent, and no meta-analysis has been undertaken to quantitatively assess this association.

Methods

We searched PubMed, Embase, and Web of Science databases for cohort articles published up to December 1, 2020. Fixed or random-effects models were used to estimate the summary relative risks (RRs) and 95% confidence intervals (CIs) of CV events in relation to IGF-1. Restricted cubic splines were used to model the dose–response association.

Results

We identified 11 articles (thirteen cohort studies) covering a total of 22,995 participants and 3040 CV events in this meta-analysis. The risk of overall CV events reduced by 16% from the highest to the lowest IGF-1 levels (RR 0.83, 95% CI 0.72–0.95), while the occurrence of CV events reduced by 28% (RR 0.72, 95% CI 0.56–0.92), but not for CV deaths, however (RR 1.00, 95% CI 0.65–1.55). We also found linear associations between IGF-1 levels and CV events. With each per 45 μg/mL IGF-1 increase, the pooled RRs were 0.91 (95% CI 0.86–0.96), 0.91 (95% CI 0.85–0.97) and 0.91 (95% CI 0.84–0.98) for overall CV events, for the occurrence of CV events, and for CV deaths, respectively.

Conclusions

Our findings based on cohort studies support the contention that any increase in IGF-1 is helpful in reducing the overall risk of CV events. As an important biomarker for assessing the likelihood of CV events, IGF-1 appears to offer a promising prognostic approach for aiding prevention.

Nur mit Berechtigung zugänglich

World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death .Accessed Dec 2020.

Roth GA, Mensah GA, Johnson CO et al (2020) Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010CrossRefPubMedPubMedCentral

NCD Countdown 2030 collaborators (2020). NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. Lancet (London, England), 396(10255):918–934. https://doi.org/10.1016/S0140-6736(20)31761-X

Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253(8):2769–2776CrossRefPubMed

Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL (1981) Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science 212(4500):1279–1281. https://doi.org/10.1126/science.6262917CrossRefPubMed

Schutte AE, Conti E, Mels CM et al (2016) Attenuated IGF-1 predicts all-cause and cardiovascular mortality in a black population: a five-year prospective study. Eur J Prev Cardiol 23(16):1690–1699. https://doi.org/10.1177/2047487316661436CrossRefPubMed

Sun J, Axelsson J, Machowska A et al (2016) Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 11(7):1163–1172. https://doi.org/10.2215/cjn.10441015CrossRefPubMedPubMedCentral

Hinojosa-Amaya JM, Varlamov EV, Yedinak CG et al (2021) Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort. J Endocrinol Invest 44(12):2665–2674. https://doi.org/10.1007/s40618-021-01579-4CrossRefPubMed

Parolin M, Dassie F, Vettor R, Steeds RP, Maffei P (2021) Electrophysiological features in acromegaly: re-thinking the arrhythmic risk? J Endocrinol Invest 44(2):209–221. https://doi.org/10.1007/s40618-020-01343-0CrossRefPubMed

10.

Vasan RS, Sullivan LM, D’Agostino RB et al (2003) Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham heart study. Ann Intern Med 139(8):642–648. https://doi.org/10.7326/0003-4819-139-8-200310210-00007CrossRefPubMed

11.

Bleumink GS, Rietveld I, Janssen JA et al (2004) Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam study). Am J Cardiol 94(3):384–386. https://doi.org/10.1016/j.amjcard.2004.04.044CrossRefPubMed

12.

van Bunderen CC, van Nieuwpoort IC, van Schoor NM, Deeg DJ, Lips P, Drent ML (2010) The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 95(10):4616–4624. https://doi.org/10.1210/jc.2010-0940CrossRefPubMed

13.

Ricketts SL, Rensing KL, Holly JM et al (2011) Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. Int J Mol Epidemiol Genet 2(3):261–285PubMedPubMedCentral

14.

Friedrich N, Haring R, Nauck M et al (2009) Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab 94(5):1732–1739. https://doi.org/10.1210/jc.2008-2138CrossRefPubMed

15.

Jing Z, Hou X, Wang Y et al (2015) Association between insulin-like growth factor-1 and cardiovascular disease risk: evidence from a meta-analysis. Int J Cardiol 198:1–5. https://doi.org/10.1016/j.ijcard.2015.06.114CrossRefPubMed

16.

Kaplan RC, McGinn AP, Pollak MN et al (2007) Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 92(4):1319–1325. https://doi.org/10.1210/jc.2006-1631CrossRefPubMed

17.

Saber H, Himali JJ, Beiser AS et al (2017) Serum insulin-like growth factor 1 and the risk of ischemic stroke: the Framingham study. Stroke 48(7):1760–1765. https://doi.org/10.1161/strokeaha.116.016563CrossRefPubMedPubMedCentral

18.

Kaplan RC, Strizich G, Aneke-Nash C et al (2017) Insulinlike growth factor binding protein-1 and ghrelin predict health outcomes among older adults: cardiovascular health study cohort. J Clin Endocrinol Metab 102(1):267–278. https://doi.org/10.1210/jc.2016-2779CrossRefPubMed

19.

Ruidavets JB, Luc G, Machez E et al (2011) Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis 218(2):464–469CrossRefPubMed

20.

Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106(8):939–944. https://doi.org/10.1161/01.cir.0000027563.44593.ccCrossRefPubMed

21.

Saydah S, Graubard B, Ballard-Barbash R, Berrigan D (2007) Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 166(5):518–526. https://doi.org/10.1093/aje/kwm124CrossRefPubMed

22.

Schneider HJ, Wallaschofski H, Völzke H et al (2012) Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS ONE 7(3):e33084. https://doi.org/10.1371/journal.pone.0033084CrossRefPubMedPubMedCentral

23.

Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo study. J Clin Endocrinol Metab 89(1):114–120. https://doi.org/10.1210/jc.2003-030967CrossRefPubMed

24.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

25.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

26.

Ohlsson C, Mohan S, Sjogren K et al (2009) The role of liver-derived insulin-like growth factor-I. Endocr Rev 30(5):494–535. https://doi.org/10.1210/er.2009-0010CrossRefPubMedPubMedCentral

27.

Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D (2012) Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 175(1):66–73. https://doi.org/10.1093/aje/kwr265CrossRefPubMed

28.

Saber H, Himali JJ, Beiser A, et al. High serum insulin-like growth factor 1 is associated with lower risk of ischemic stroke: The framingham heart study. Stroke Conference: American Heart Association/American Stroke Association. 2015;46(1).

29.

Hamling J, Lee P, Weitkunat R, Ambühl M (2008) Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27(7):954–970. https://doi.org/10.1002/sim.3013CrossRefPubMed

30.

Bekkering GE, Harris RJ, Thomas S et al (2008) How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis? Am J Epidemiol 167(9):1017–1026. https://doi.org/10.1093/aje/kwn005CrossRefPubMed

31.

Greenland S (1995) Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6(4):356–365. https://doi.org/10.1097/00001648-199507000-00005CrossRefPubMed

32.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRefPubMedPubMedCentral

33.

Liu X, Zhang D, Liu Y et al (2017) Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies. Hypertension 69(5):813–820. https://doi.org/10.1161/hypertensionaha.116.08994 (Dallas, Tex : 1979)CrossRefPubMed

34.

Cai Z, Fan X (2020) A comparison of fixed-effects and random-effects models for multivariate meta-analysis using an SEM approach. Multivariate Behav Res 55(6):839–854. https://doi.org/10.1080/00273171.2019.1689348CrossRefPubMed

35.

Allison PD. Fixed Effects Regression Models. SAGE. 2006

36.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed

37.

Saber H, Himali JJ, Beiser AS et al (2017) Serum insulin-like growth factor 1 and the risk of ischemic stroke. Stroke 48(7):1760–1765CrossRefPubMedPubMedCentral

38.

Obradovic M, Zafirovic S, Soskic S et al (2019) Effects of IGF-1 on the cardiovascular system. Curr Pharm Des 25(35):3715–3725. https://doi.org/10.2174/1381612825666191106091507CrossRefPubMed

39.

Higashi Y, Gautam S, Delafontaine P, Sukhanov S (2019) IGF-1 and cardiovascular disease. Growth Horm IGF Res 45:6–16. https://doi.org/10.1016/j.ghir.2019.01.002CrossRefPubMedPubMedCentral

40.

Johnsen SP, Hundborg HH, Sørensen HT et al (2005) Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 90(11):5937–5941. https://doi.org/10.1210/jc.2004-2088CrossRefPubMed

41.

De Lorenzo A, Moreira AS, Souza EG, Oliveira GM (2016) Insulin-like growth factor-1 in early-onset coronary artery disease: insights into the pathophysiology of atherosclerosis. Int J Cardiol 202:1–2. https://doi.org/10.1016/j.ijcard.2015.04.032CrossRefPubMed

42.

Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ (2013) The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 9(6):366–376. https://doi.org/10.1038/nrendo.2013.67CrossRefPubMedPubMedCentral

43.

Perkel D, Naghi J, Agarwal M et al (2012) The potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther 17(1):72–78. https://doi.org/10.1177/1074248411402078CrossRefPubMed

44.

Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C (1999) Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol 17(3):813–817. https://doi.org/10.1200/jco.1999.17.3.813CrossRefPubMed

45.

Landin-Wilhelmsen K, Wilhelmsen L, Lappas G et al (1994) Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 41(3):351–357. https://doi.org/10.1111/j.1365-2265.1994.tb02556.xCrossRef

46.

Foncea R, Andersson M, Ketterman A et al (1997) Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 272(31):19115–19124. https://doi.org/10.1074/jbc.272.31.19115CrossRefPubMed

47.

Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P (2001) Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol 33(10):1777–1789. https://doi.org/10.1006/jmcc.2001.1441CrossRefPubMed

48.

Patel VA, Zhang QJ, Siddle K et al (2001) Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res 88(9):895–902. https://doi.org/10.1161/hh0901.090305CrossRefPubMed

49.

Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR (1996) Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 137(5):1798–1803. https://doi.org/10.1210/endo.137.5.8612517CrossRefPubMed

50.

Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S (2014) New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab 25(3):128–137. https://doi.org/10.1016/j.tem.2013.12.002CrossRefPubMed

51.

Arcopinto M, Bobbio E, Bossone E et al (2013) The GH/IGF-1 axis in chronic heart failure. Endocr Metab Immune Disord Drug Targets 13(1):76–91. https://doi.org/10.2174/1871530311313010010CrossRefPubMed

52.

Castellano G, Affuso F, Conza PD, Fazio S (2009) The GH/IGF-1 axis and heart failure. Curr Cardiol Rev 5(3):203–215. https://doi.org/10.2174/157340309788970306CrossRefPubMedPubMedCentral

53.

Chennaoui M, Léger D, Gomez-Merino D (2020) Sleep and the GH/IGF-1 axis: consequences and countermeasures of sleep loss/disorders. Sleep Med Rev 49:101223. https://doi.org/10.1016/j.smrv.2019.101223CrossRefPubMed

54.

Saccà L, Cittadini A, Fazio S (1994) Growth hormone and the heart. Endocr Rev 15(5):555–573. https://doi.org/10.1210/edrv-15-5-555CrossRefPubMed

55.

Rosén T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336(8710):285–288. https://doi.org/10.1016/0140-6736(90)91812-oCrossRefPubMed

56.

Gravholt CH, Viuff MH, Brun S, Stochholm K, Andersen NH (2019) Turner syndrome: mechanisms and management. Nat Rev Endocrinol 15(10):601–614. https://doi.org/10.1038/s41574-019-0224-4CrossRefPubMed

57.

Oldfield EH, Jane JA Jr, Thorner MO, Pledger CL, Sheehan JP, Vance ML (2017) Correlation between GH and IGF-1 during treatment for acromegaly. J Neurosurg 126(6):1959–1966. https://doi.org/10.3171/2016.8.Jns161123CrossRefPubMed

58.

Bruch C, Herrmann B, Schmermund A, Bartel T, Mann K, Erbel R (2002) Impact of disease activity on left ventricular performance in patients with acromegaly. Am Heart J 144(3):538–543. https://doi.org/10.1067/mhj.2002.123572CrossRefPubMed

59.

Wright AD, Hill DM, Lowy C, Fraser TR (1970) Mortality in acromegaly. Q J Med 39(153):1–16PubMed

60.

Friehs I, Stamm C, Cao-Danh H, McGowan FX, del Nido PJ (2001) Insulin-like growth factor-1 improves postischemic recovery in hypertrophied hearts. Ann Thorac Surg 72(5):1650–1656. https://doi.org/10.1016/s0003-4975(01)03098-3CrossRefPubMed

61.

Li B, Setoguchi M, Wang X et al (1999) Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 84(9):1007–1019. https://doi.org/10.1161/01.res.84.9.1007CrossRefPubMed

62.

Anwar A (2002) Tumor necrosis factor-α regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle. Circulation 105(10):1220–1225CrossRefPubMed

Titel: Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose–response meta-analysis of cohort studies
verfasst von: T. Li
Y. Zhao
X. Yang
Y. Feng
Y. Li
Y. Wu
M. Zhang
X. Li
H. Hu
J. Zhang
L. Yuan
Y. Liu
X. Sun
P. Qin
C. Chen
D. Hu
Publikationsdatum: 01.12.2022
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 12/2022
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-022-01819-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

DNA methylation and waist-to-hip ratio: an epigenome-wide association study in Chinese monozygotic twins

Andrological effects of SARS-Cov-2 infection: a systematic review and meta-analysis

Efficacy of short-term induction therapy with low-dose testosterone as a diagnostic tool in the workup of delayed growth and puberty in boys

Maternofetal outcomes in early-onset gestational diabetes: does weight gain matter?

Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence